Search hospitals > California > Fremont

Center for Dermatology Clinical Research, Inc.

Claim this profile
Fremont, California 94538
Global Leader in Atopic Dermatitis
Global Leader in Dermatitis
Conducts research for Medical Device Dermatitis
Conducts research for Psoriasis
Conducts research for Acne
94 reported clinical trials
1 medical researcher
Photo of Center for Dermatology Clinical Research, Inc. in FremontPhoto of Center for Dermatology Clinical Research, Inc. in FremontPhoto of Center for Dermatology Clinical Research, Inc. in Fremont

Summary

Center for Dermatology Clinical Research, Inc. is a medical facility located in Fremont, California. This center is recognized for care of Atopic Dermatitis, Dermatitis, Medical Device Dermatitis, Psoriasis, Acne and other specialties. Center for Dermatology Clinical Research, Inc. is involved with conducting 94 clinical trials across 64 conditions. There are 1 research doctors associated with this hospital, such as Sunil Dhawan.

Top PIs

Clinical Trials running at Center for Dermatology Clinical Research, Inc.

Atopic Dermatitis
Dermatitis
Plaque Psoriasis
Eczema
Gorlin Syndrome
Lichen Simplex Chronicus
Psoriasis
Acne
Chronic Urticaria
Medical Device Dermatitis
Image of trial facility.

Amlitelimab

for Eczema

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 \[COAST-1\], EFC17560 \[COAST 2\], EFC17561 \[SHORE\]) and were responders can maintain their response either remaining at dose 1 or switching to dose 2 of amlitelimab compared to treatment withdrawal. Study details include: The study duration will be up to 68 weeks including a 52-week randomized double-blind period, and a 16-week safety follow-up for participants not entering the LTS17367 (RIVER-AD). The study duration will be up to 52 weeks for participants entering the LTS17367 \[RIVER-AD\] study at the Week 52 visit of EFC17600 (ESTUARY). The total treatment duration will be up to 52 weeks. The total number of visits will be up to 15 visits (or 14 visits for those entering LTS17367 \[RIVER-AD\] study).
Recruiting1 award Phase 33 criteria
Image of trial facility.

Amlitelimab

for Atopic Dermatitis (COAST 1)

This trial tests an injectable treatment called amlitelimab for people aged 12 and older with moderate to severe eczema that doesn't respond well to creams or ointments. The treatment aims to reduce skin inflammation and itching by blocking specific proteins in the immune system. The study will evaluate how effective and safe amlitelimab is.
Recruiting1 award Phase 33 criteria
Image of trial facility.

FB825

for Eczema

This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
Recruiting0 awards Phase 25 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Center for Dermatology Clinical Research, Inc.?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security